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ipolar disorder (manic depressive illness)
affects approximately 1% to 2% of the population,and
as many as 3.9% when bipolar I disorder and bipolar II
disorder are aggregated.
1-3While the prevalence of bipo-
lar disorder (BD) is comparable in men and women,
there are several aspects of bipolar disorder that require
unique consideration in women.This manuscript reviews
the course of illness considerations for women with bipo-
lar disorder,how bipolar disorder impacts reproductive
function in women,and considerations for the treatment
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While the treatment of bipolar disorder (BD) is typically complex, the treatment of women with bipolar disorder is
even more challenging because clinicians must also individualize treatment based on the potential for pregnancy,
drug interactions with oral contraceptives, and an increased risk of endocrine diseases that can either impact the
course of illness or become manifest with some treatments. Women with BD should be checked for hypothyroidism,
and if prescribed antidepressants, carefully watched for rapid cycling or a mood switch to mania, hypomania, or a
mixed state. Several medications interact with oral contraceptives or increase the risk of developing polycystic ovary
syndrome. Consideration of possible pregnancy is essential, and should be planned in advance whenever possible.
Rates of recurrence have been shown to be equal in pregnant and nonpregnant women with BD. Risks of medica-
tion to the fetus at various points of development must be balanced against the risks of not treating, which is also
detrimental to both fetus and mother. The postpartum period is a time of especially high risk; as many as 40% to
67% of women with BD report experiencing a postpartum mania or depression. The decision to breastfeed must also
take into account the adverse impact of sleep deprivation in triggering mood episodes. In order to best address these
issues, clinicians must be familiar with the data and collaborate with the patient to assess risks and benefits for the
individual women and her family.  
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bipolar disorder
There are few clinical characteristics that reliably differ-
entiate men and women with bipolar disorder.Multiple
authors have reported that women experience more
depressive episodes over the course of their illness com-
pared with men.
4-6 However, the concern that women
may be more willing to report a prior depressive episode
has not received adequate attention.It is also reported





13 compared with men with bipo-
lar disorder.Burt and Rasgon
14 point out that this differ-
ence may be due to inadequate mood stabilization and
excessive use of antidepressants in women.Recent ran-
domized evidence suggests that antidepressants added to
adequate doses of antimanic medications do not improve
outcomes in bipolar depression.
15Taken together,at this
juncture,when a woman with bipolar disorder presents
with depression or rapid cycling, it appears prudent to
optimize mood stabilizers, check for hypothyroidism
(which is more common in women),and judiciously re-
evaluate the use of antidepressant medications.
The impact of menses and menopause 
on the course of illness of women 
with bipolar disorder
Evidence on the impact of the menstrual cycle on course
of illness of bipolar disorder remains mixed.Some stud-
ies report that women with bipolar disorder report fre-
quent premenstrual mood disturbances,
16-17 while other
studies report mixed findings.
13,18 Little is known about
the influence of menopause on bipolar disorder in
women. Various reports suggest that menopause can
improve, worsen, or not impact the course of mood
symptoms in women with bipolar disorder.
19 Blehar et al
16
found that as many as 20% of postmenopausal women
with bipolar disorder reported severe emotional distur-
bances during the menopausal transition. Some
researchers have described this as a conversion to a rapid
cycling variant of bipolar disorder.
20 More data is needed
to understand whether these hormonal transitions
directly impact the course of bipolar illness.Careful eval-
uation of individual women with respect to menses and
menopausal status appears warranted,with the institu-
tion of symptomatic treatment,if needed.
The impact of pregnancy and the 
postpartum period on the course of 
illness of bipolar disorder
A common misconception is that pregnancy is protective
against psychiatric symptoms.Data clearly indicate that
this is not the case in bipolar disorder, where rates or
recurrence have been shown to be equal in pregnant and
nonpregnant women.
21 Factors associated with a higher
risk of relapse during pregnancy include abrupt discon-
tinuation of mood stabilizers,a history of four or more
prior mood episodes, and prior intrapartum mood
episode(s).
21
The postpartum period is a time of particularly high risk
for women.While estimates vary,the risk for relapse dur-
ing the puerperium range from 20% to 50%.
22-24As many
as 40% to 67% of women with BD report experiencing a
postpartum mania or depression.
25-26Women with BD have
a 100-fold higher risk than women without a psychiatric
illness history of experiencing postpartum psychosis.This
form of psychosis usually starts within 3 weeks of child-
birth,and the initial presentation is often delusions.
27-28 It
is important to differentiate postpartum depression from
the “baby blues.”Baby blues consist of mood lability and
depressed mood and occurs during the first 2 weeks post-
partum, but does not persist and is not associated with
delusions or marked impairment of functioning.
Medication effects in women 
with bipolar disorder
Differences in treatment response
Currently,little is known about what medications might
be associated with most benefit in women with bipolar
disorder.At present,only lithium response has been well
studied.In a meta-analysis of 17 lithium treatment stud-
ies,there was no gender difference in response to lithium
observed.
29 The following sections will address other
medication effects that may impact choice of treatment
for women with bipolar disorder.
Menstrual and ovarian changes related to medication
treatments 
Polycystic ovary syndrome (PCOS) is a serious endocrine
disorder that affects women in their reproductive years.
30-
Clinical research
23032 PCOS is a syndrome defined by the presence of: (i)
ovulatory dysfunction (ie,polymenorrhea,oligomenor-
rhea,or amenorrhea);(ii) clinical evidence of hyperan-
drogenism or hyperandrogenemia;and (iii) exclusion of
other endocrinopathies (eg,hyperprolactinemia,thyroid
dysfunction,adrenal hyperplasia,or Cushing syndrome).
33
PCOS is the leading cause of anovulatory infertility and
hirsutism,and is associated with multiple reproductive,
metabolic disorders,and general health disorders,includ-
ing increased risk of miscarriage, insulin resistance,
hyperlipidemia,cardiovascular disease,and endometrial
cancer. In the general population of reproductive-age
women, the prevalence of PCOS is estimated to be
between 4% and 7%,but may be as high as 11%.
32,34
An association between the development of PCOS and
the use of antiepileptic drugs (AEDs) was first suggested
by Isojarvi et al.
35This study looked at the prevalence of
PCOS spectrum symptoms in 238 women with epilepsy,
and suggested that use of valproate is associated with an
increase in reproductive disorders.In a follow-up study,
36
12 women with epilepsy were switched from valproate to
lamotrigine, to assess whether changes in body mass
index,insulin levels,and associated other symptoms were
reversible.Twelve months after switching,the 12 women
had lost weight and exhibited decreased BMI, insulin,
and testosterone levels.The number of women with poly-
cystic ovaries decreased from 11 to 7, and the number
with menstrual abnormalities decreased from 7 to 2.
While these findings raised concern for the use of val-
proate in women, the studies were all conducted in
women with epilepsy,and it was unclear if the association
would be present in other groups. Subsequent studies
assessed the relationship of valproate use and risk for
PCOS in women with bipolar disorder. Rasgon et al
37
conducted a small pilot study in 22 women with bipolar
disorder, receiving lithium monotherapy, valproate
monotherapy,or lithium-valproate combination therapy.
None of the patients in the study met criteria for PCOS,
and there was no relationship between valproate or
lithium therapy and PCOS. She followed this with a
larger cross-sectional trial including 96 women,aged 18
to 45,who were being treated for a DSM-IV diagnosis of
bipolar disorder I,II or NOS,and who had received long-
term treatment with an antimanic agent through the
Stanley Foundation Treatment Network.
38 Of the 80
women with complete questionnaire data, 52 (65%)
reported current menstrual abnormalities.While only 15
women (38%) reported new menstrual abnormalities
since treatment for bipolar disorder,14 of these occurred
since treatment with valproate (P=0.04).No significant
differences were observed between women receiving or
not receiving valproate in mean levels of free or total
serum testosterone levels (n=72).Of the 50 women tak-
ing VPA,3 (6%) met criteria for PCOS< compared with
0% of the 22 women taking other antimanic medications
(P=0.20).
Another small study included 38 women with bipolar dis-
order,receiving valproate or lithium monotherapy for at
least 2 years.
39 Menstrual irregularities were reported by
50% of the valproate-treated patients and 15% of the
lithium-treated patients. Free testosterone and
androstenedione levels were significantly higher than the
reference range in valproate-treated patients, and LH
was elevated in both treatment groups.The investigators
concluded that valproate may result in some aspects of
the metabolic syndrome in some women with bipolar dis-
order.This study is limited by its small size and lack of a
control group.
Joffe et al
40 examined 300 women with bipolar disorder,
between the ages of 18 and 45, participating in the
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD).Medication and menstrual-cycle
histories were obtained, and hyperandrogenism was
assessed.Among 230 women with complete assessments,
oligomenorrhea with hyperandrogenism developed in 9
of 86 (10.5%) women on valproate and in 2 of 144
(1.4%) women on an alternative anticonvulsant or
lithium (relative risk 7.5, 95% CI 1.7–34.1, P=0.002).
When it occurred,oligomenorrhea began within the first
12 months of valproate use.This study demonstrated an
association between valproate and new-onset oligomen-
orrhea with hyperandrogenism in women with bipolar
disorder.A subsequent follow-up study completed fol-
low-up assessments (after 17+/-7-months) in 14 women
(5/9 with treatment-emergent PCOS,9/19 valproate use
″6 months).
41 Of 7 women who developed valproate-asso-
ciated PCOS,reproductive features of PCOS remitted in
3/4 women discontinuing valproate and persisted in all 3
continuing valproate.Compared with women continuing
valproate,menstrual-cycle irregularities improved among
valproate discontinuers whose PCOS features remitted
(P=0.01).There was a trend toward lower serum testos-
terone (P=0.06).Body weight was unchanged.
Valproate may also be associated with PCOS features
because increase in body weight or insulin resistance sec-
ondary to valproate therapy
36,42-43 may lead to the devel-
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231opment of PCOS through insulin effects in the ovary.
44
However, menstrual-cycle irregularities or PCOS are
uncommon in women with obesity or type 2 diabetes.
45-47
Prospective research is needed to examine the relation-
ship between weight,insulin resistance,and predisposi-
tion or development of PCOS features.
The collective literature demonstrates that rates of men-
strual disturbances are high in women with bipolar dis-
order, regardless of their treatment history. It appears
that treatment with valproate further predicts the devel-
opment of menstrual abnormalities and an increase in
testosterone levels over time.However,little is known
about the additive impact of previous exposure,duration
of exposure,and age of women who are most vulnerable
to development of this constellation of symptoms.
48 More
research is needed to understand the relationship
between etiology of reproductive and hormonal irregu-
larities,onset of bipolar disorder,and treatment history.
Endocrine effects of medication treatments 
Women are at greater risk than men for the development
of lithium-associated hypothyroidism.Clinical hypothy-
roidism during lithium treatment is present in 14% of
women, versus 5.5% of men.
49 Lithium-treated women
may also be at higher risk for lithium-induced thyroiditis.
13
Effects of pharmacotherapy on oral contraceptives
The efficacy of oral contraception (OC) can be impaired
by concomitant use of medications that induce liver
enzymes (eg,carbamazepine,oxcarbazepine),which may
be secondary to enhanced hepatic metabolism of the OC
hormones. Therefore, if women are prescribed these
medications for treatment of symptoms of bipolar disor-
der,clinicians should advise them to use barrier methods
of birth control,monitor for spotting,and/or work with
the gynecologist to increase oral contraceptive pill (OCP)
dose.Conversely,OCPs induce lamotrigine metabolism,
such that increased lamotrigine doses are often required
for women on OCPs.While no drug–drug interactions
with OC have been reported to date with valproate,
lithium, or the atypical antipsychotics, further study is
required in women with bipolar disorder.
In summary, there is no systematic controlled data to
demonstrate that certain treatments or more effective for
men and women. Instead, providers should carefully
weigh potential side effects and interactions associated
with treatments, and the importance of those risks for
individual women.
Treatment of bipolar disorder during 
pregnancy and postpartum
Medication use during pregnancy
We strongly recommend that clinicians discuss plans for
conception with all women with bipolar disorders who
are of childbearing potential.Recent work suggests that
when women with bipolar disorder are provided accurate
and balanced information about the potential risks and
benefits they face,37% choose not to pursue pregnancy.
50
Prenatal counseling should include discussion of possible
risks of taking medications during pregnancy,risks to the
patient and child of escalating or uncontrolled symptoms
of bipolar disorder,and the risk of genetic transmission
of bipolar disorder to the child.
14
In bipolar women who are pregnant,the use of medica-
tions must be assessed in terms of adverse fetal or neona-
tal effects, in addition to the usual concerns for effec-
tiveness,tolerability,and safety for the mother.Before
pregnancy begins,the patient,family,and clinician should
detailed a plan of potential interventions in case of recur-
rences or exacerbations of mood episodes.For example,
deciding if electroconvulsive therapy,which is relatively
safe in pregnancy, would be the first choice if a severe
depressive episode occurred.
One of the most difficult problems for women with bipo-
lar disorder is the lack of effective nonteratogenic treat-
ments.First-trimester exposure to the traditional mood
stabilizers (lithium, valproate, and carbamazepine) is
associated with an increased risk of fetal malformations.
51-53
Given this risk, many women with bipolar disorder
choose to discontinue medications during pregnancy and
sometimes,while trying to conceive.When this is done
abruptly,women are at increased risk for relapse.Viguera
et al
21 reported recurrence rates following lithium dis-
continuation in a cohort of 101 pregnant and nonpreg-
nant women.Over the 64-week period following lithium
discontinuation, recurrences occurred in 85.7% of the
pregnant/postpartum women and 67.8% of the non-
pregnant women. Recurrence rates were less when
lithium was discontinued via a gradual taper (15 to 30
days).In some cases,it is preferable to continue the med-
ication while carefully monitoring fetal development with
high-resolution ultrasound.
Clinical research
232Once the high risk associated with first-trimester expo-
sure to certain medications has passed, many women
who had discontinued medication then consider restart-
ing pharmacotherapy.There is no clear guidance as to
whether this should be done automatically,or whether it
is preferable to wait for early signs of potential relapse.
In women with a history of self-harm or protracted
recovery from previous episodes,impaired insight,or a
strained support system,reinstatement of pharmacolog-
ical treatment may reduce overall risk to both mother
and fetus.
54
Several careful reviews of medications useful in bipolar
disorder and their implications for pregnancy and post-
partum use are available
14,54-58 An overview of safety con-
cerns for commonly used treatments is presented in
Table I.It should be noted that much of what is known
about the safety parameters of anticonvulsant drugs
come from registries of epileptic women, and safety
information for other classes of drugs also stem from
diverse diagnostic subgroups.
General recommendations for treatment of bipolar
women during pregnancy include minimizing pharma-
cotherapy if clinically feasible,particularly during the first
trimester.
14 If treatment is initiated or continued,use of
monotherapy at the minimal effective dose is recom-
mended. Given that lamotrigine monotherapy has the
largest safety database,Gentile
56 suggests this agent as
the first-line mood stabilizer during pregnancy.In preg-
nancies with risk for neural tube deficits, folate is pre-
scribed at 4 mg/day,compared with 0.4 mg.prescribed in
lower-risk pregnancies.
Treatment during the postpartum period, and while
breastfeeding
Regardless of whether a mood episode occurs during
pregnancy,the postpartum period is associated with par-
ticularly high risk for relapse.Women with bipolar disor-
der have a 100-fold higher risk than women without a his-
tory of psychiatric illness of developing a postpartum
psychosis.
27 Some suggest beginning prophylaxis in the sec-
ond or third trimester of pregnancy,when there is less ter-
atogenic risk
59,60 although there is no consensus on when to
begin prophylaxis.
61 During pregnancy,the patient and her
doctor must make plans for the postpartum period,includ-
ing discussion of options for prophylaxis.
Several studies have suggested the positive benefits of pro-
phylaxis.A small open-label study of women at risk for
puerperal psychosis (women with bipolar disorder diag-
noses, or previous episodes of postpartum psychosis)
added lithium prophylaxis in the third trimester of preg-
nancy or immediately after delivery. Of 21 women
observed, only 2 had a recurrence of their psychotic ill-
ness.
60Another small study included 27 women with bipo-
lar disorder.
62 Only 1 of the 14 patients starting prophy-
lactic agents during the postdelivery period relapsed
within the first 3 postpartum months,while 8 of the 13 who
did not receive prophylaxis showed evidence of recurrent
mood instability during those 3 months.Similar positive
benefits were observed in other small studies.
63-64
In contrast,Wisner et al
65 offered divalproex plus symp-
tom monitoring, or symptom monitoring alone, for
immediate postpartum management of 26 women with
bipolar disorder.There were no significant differences
between groups in the proportions of women who devel-
oped postpartum mood episodes over the 20-week obser-
vation period. The time to development of a mood
episode also did not vary between groups.
Treatment decisions about medication use postpartum
should be based on the mother’s clinical status and pre-
vious course,regardless of breastfeeding status.
14 In other
words,the mother’s health and stability should take pri-
ority over the feeding method of the infant.While breast-
feeding is associated with many potential benefits to both
mother and child, the sleep disruption associated with
being the sole source of food for a newborn is con-
traindicated for many bipolar women.
55Women should
explore options to ensure adequate sleep, including
arranging for other adults to feed the infant,and express-
ing milk earlier in the day for night feedings.The mother
and her partner should be educated about the possible
risks of breastfeeding while taking medication,and the
infant should be monitored as needed.Again,monother-
apy with the lowest possible dose of medication is the
preferred treatment option,if pharmacotherapy is pur-
sued.
Nonpharmacological treatment options during 
pregnancy and lactation
Because of concerns over the use of traditional medica-
tions during pregnancy,there has been great interest in
exploring the utility of omega-3 fatty acids for women
planning pregnancy,pregnant,or lactating.Unlike tradi-
tional treatments, addition of omega-3 fatty acids may
benefit both mother and fetus, as adequate intake of
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infant brain and nervous system development, and
(DHA) is selectively transferred to the developing fetus
during pregnancy.
66-73 Stores of eicosopentaenoic acid
(EPA) are progressively depleted during pregnancy.
74
Hibbeln and Salem
75 have hypothesized that this may
predispose women to affective episodes.Additionally,
research suggests that pregnant women only achieve
20% to 60% of recommended omega-3 fatty acid
intake.
76 Omega-3 fatty acids (DHA + EPA) have been
administered to pregnant women with various other dis-
orders,without adverse effects.
77-79
A small randomized placebo-controlled study assessed the
benefit of an omega-3 fatty acid (DHA) in women plan-
ning pregnancy.
80This study also incorporated a brief psy-
chosocial educational intervention,involving the woman
and close supporters.The 10 participants tolerated the trial
well,with no serious adverse events reported.Two of the
Clinical research
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Table I. Risks of common psychotropics for the treatment of bipolar disorder during pregnancy and while breastfeeding.(continued on next page)
Medication Risk in pregnancy Breastfeeding risk
Lithium Risk for cardiovascular abnormalities, most notably  Contraindicated for use with breastfeeding by the
Ebstein’s anomaly, incidence ranges from 4%-12%.  American Academy of Pediatrics Committee on Drugs.
Risk for toxicity. High concentrations of the drug present in infant serum and
Other risks include premature delivery, floppy infant  breastmilk (24%-72% of maternal serum concentration).
syndrome, transient neurodevelopmental deficits,   Can be associated with rapid dehydration in febrile infants.
nephrogenic diabetes insipdus, thyroid dysfunctions,   Other detrimental effects can include lethargy, hypothermia,
and rarely polyhydramnios. hypotonia, and T-wave modifications on electrocardiogram.
Valproate (VPA) VPA use in pregnancy associated with an approximately Classified as compatible with breastfeeding
2-5 fold increased risk of major malformations,  by the American Academy of Pediatrics Committee
especially if administered in the first trimester. Overall  on Drugs.
incidence of major malformations is 11%. Most common  Present in the serum of breastfed infants (%<1-10%).
risks include spina bifida (1%-5% risk), developmental In one 3-month infant, thrombocytopenic
retardation, skeletal malformations, and cardiovascular   purpura and anemia were attributed to valproate
abnormalities. “Fetal valproate syndrome” includes   exposure through placenta and breast milk.
cardiovascular, craniofacial, urogenital, digital,  
repiratory tract abnormalitiesand developmental delay.  
Increased risk for miscarriage and/or stillbirth.
Carbamazepine  Overall incidence of CBZ-related fetal malformations Classified as compatible with breastfeeding by the
(CBZ) is 5.7%. They include microcephaly, other cranio-facial American Academy of Pediatrics Committee on Drugs.
skeletal deficits, growth retardation, and cardiac Present in breast milk (7%-95%) and serum (6%-65%)
deficits. The association between neural tube defects, of breastfed infants; no widespread adverse effects
cardiovascular and urinary tract anomalies, and cleft   noted for breastfed infants. Carbamazepine
palate in neonates exposed to the compound is called   is metabolized rapidly in newborns.
“carbamazepine syndrome.” Increased risk for spina  
bifida (0.5%-1.0%). Also associated with fetal vitamin-K  
deprivation, resulting in increased risk for neonatal
bleeding and midfacial abnormalities.
Lamotrigine (LTG) Lesser risk for malformations compared with other Present in the serum of breastfed infants (range from
anticonvulsants. In epilepsy, birth defects observed in 23%-33% of maternal levels); monitoring for rash
2.9% of pregnant women exposed to LTG monotherapy.  in infants recommended. The manufacturer does not
One report that doses >200 mg/day may be associated  recommend use during breastfeeding.
with increased risk for major malformations.
First-generation  Important treatment options for acute mania during No adverse effects noted in breastfed
antipsychotics pregnancy; low doses for ongoing therapy for those infants exposed to these drugs.
who want a less teratogenic option.
Association with hyperprolactinemia.women in the active group completed the 52-week trial
(33.3%),and of those with premature discontinuation,3
were due to emerging or worsening mood symptoms
(50%) and 1 due to noncompliance.Of the 3 women with
emerging symptoms,1 had predominantly anxiety and two
had emerging hypomania. Three of those receiving
placebo completed the 52 weeks (75%),with 1 (25%) dis-
continuing due to irritability.While there was no statisti-
cally significant difference between groups,the numbers
in cells are admittedly small.Three women conceived and
ultimately delivered healthy babies (1 in the DHA group,
2 in the placebo group).
Additionally, psychotherapy is a potential alternative
treatment during pregnancy or postpartum for women
with only mild-to-moderate depressive symptoms.These
are best managed with cognitive behavioral therapy,
interpersonal therapy,or family focused therapy.
81-85
While electroconvulsive therapy (ECT) is another non-
pharmacological option for treatment during pregnancy,
it should be reserved for severe cases, such as women
hospitalized in a severe vegetative state or psychotic
episode.As noted above,there is no indication of terato-
genesis associated with ECT,
86 and the treatment is con-
sidered relatively safe during pregnancy.
87
Women and their providers should carefully discuss treat-
ment options during pregnancy and the postpartum
period.While most experts agree that medication use dur-
ing the first trimester should be minimized, there are
options for conservative treatment in the remainder of
pregnancy and postpartum.Additionally,there are non-
pharmacological options such as omega-3 fatty acids or
psychotherapy, and ECT for severe cases. Women and
their partners should plan ahead to ensure adequate social
support and assistance with infant care to minimize sleep
disruption and stress that may increase the risk for relapse.
Summary
While the prevalence of bipolar disorder is comparable in
men and women,there are several aspects of the disorder
that require unique consideration in women.Women with
bipolar disorder should be checked for hypothyroidism
and,if prescribed antidepressants,carefully watched for
rapid cycling or a mood switch to mania,hypomania,or a
mixed state.Several medications interact with oral con-
traceptives or increase the risk of developing PCOS,and
this should be considered when choosing a medication for
women of childbearing potential.Consideration of possi-
ble pregnancy is essential, and should be planned in
advance whenever possible. Decisions about treatment
while trying to conceive and once pregnant,risks of med-
ication to the fetus at various points of development must
be balanced against the risks of not treating,which is also
detrimental to both fetus and mother.However,medica-
tions differ in their teratogenic risk,and there are options
for discussion.The postpartum period is a time of espe-
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Table I. Continued
Medication Risk in pregnancy Breastfeeding risk
Second-generation Little safety data on use in pregnant women. These drugs are secreted into breast
antipsychotics Preliminary indication is that the atypical antipsychotics milk in relatively small amounts.
are not associated with increased rates of major structural
malformations. These drugs may impact fetal development
because of known association with metabolic abnormalities
in the mother; olanzapine associated with gestational
diabetes and preeclampsia.
Antidepressants Labeling added in 2004 for physicians to consider tapering use of 
these medications near the end of the third trimester. This action 
aims to reduce jitteriness, irritability, feeding difficulties, trouble 
breathing, and other problems sometimes seen in newborns 
whose mothers took selective serotonin reuptake inhibitors (SSRIs) 
or serotonin and norepinephrine reuptake inhibitors shortly before 
delivery. Such problems usually are mild and disappear by 2 weeks 
of age. Paroxetine associated with increased risk of cardiovascular 
malformations, especially ventricular septal defects. Rare pulmonary 
hypertension with SSRIs, especially after 20 weeks' exposure.cially high risk,and most women should resume pharma-
cotherapy.The decision to breastfeed must also consider
the adverse impact of sleep deprivation in triggering mood
episodes. The care of women with bipolar disorder
requires a strong clinician-patient relationship and collab-
orative planning and decision-making. ❏
Clinical research
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Temas de actualidad del trastorno bipolar en
la mujer
Aunque el tratamiento del trastorno bipolar (TB) es
particularmente complejo, cuando se refiere a
mujeres es aun más desafiante ya que los clínicos
deben también individualizar el tratamiento consi-
derando la posibilidad de embarazo, las interaccio-
nes de los fármacos con anticonceptivos orales y el
mayor riesgo de enfermedades endocrinas, las cua-
les pueden afectar tanto el curso de la enfermedad
como aparecer con algunos tratamientos. Las muje-
res con TB deben ser evaluadas para hipotiroidismo,
y de prescribirse antidepresivos, debe observarse
cuidadosamente los ciclos rápidos o un viraje hacia
manía, hipomanía o un cuadro mixto. Algunos
medicamentos interactúan con anticonceptivos ora-
les o aumentan el riesgo de desarrollar el síndrome
de ovario poliquístico. Es esencial la consideración
de un posible embarazo y cuando sea posible éste
debe planificarse con antelación. Las frecuencias de
recurrencia se han encontrado equivalentes en
mujeres con TB con o sin embarazo. Los riesgos de
la medicación sobre el feto en diversos momentos
del desarrollo deben ser balanceados en función del
riesgo de no tratar la patología, lo que también es
perjudicial tanto para la madre como para el feto.
El período del postparto es especialmente un
tiempo de alto riesgo, ya que 40% a 67% de las
mujeres con TB refieren experimentar una depre-
sión o una manía postparto. La decisión de ama-
mantar también debe tomar en consideración el
impacto adverso de la privación de sueño como
gatillo de episodios de alteración del ánimo. Con el
objetivo de tratar lo mejor posible estos temas, los
clínicos deben estar familiarizados con la informa-
ción disponible y colaborar con el paciente en la
evaluación de los riesgos y beneficios para cada
mujer y su familia. 
Sujets actuels : femmes et troubles 
bipolaires
Le traitement des troubles bipolaires est déjà com-
plexe en lui-même, mais celui des femmes atteintes
de troubles bipolaires l’est encore plus. En effet, les
médecins doivent tenir compte de la possibilité de
grossesse, d’interactions médicamenteuses avec la
contraception orale, d’augmentation du risque de
maladies endocriniennes, qui peuvent soit influer
sur l’évolution de la maladie soit apparaître avec
certains traitements. Les femmes bipolaires doivent
être surveillées, à la recherche d’une hypothyroïdie
éventuelle, et, si elles sont sous antidépresseurs, sur-
veillées attentivement pour  la survenue de cycles
rapides ou virage de l’humeur vers un état mania-
que, hypomaniaque ou mixte. Plusieurs médica-
ments interagissent avec la contraception orale ou
augmentent le risque de développer un syndrome
des ovaires polykystiques. La prise en considération
d’une grossesse éventuelle est essentielle et celle-ci
doit être planifiée aussi tôt que possible. Les taux
de récidives thymiques sont équivalents que les
femmes bipolaires soient enceintes ou non. Il faut
peser les risques du traitement sur le fœtus aux dif-
férents stades de son développement par rapport
aux risques de l’absence de traitement, également
préjudiciable à la mère et au fœtus.  La période du
post-partum est particulièrement à risque ; 40 à 67
% des femmes bipolaires ont présenté un épisode
maniaque ou dépressif pendant cette période. La
privation de sommeil, facteur déclenchant des trou-
bles de l’humeur, doit être prise en compte dans la
décision d’allaiter. Afin de mieux prendre ces ques-
tions en considération, les médecins doivent s’in-
former des données récentes et faire participer la
patiente à l’évaluation des risques et des bénéfices
pour chaque femme et sa famille.Women and bipolar disorder - Marangell Dialogues in Clinical Neuroscience - Vol 10 . No.2 . 2008
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